ImmuneOnco IMM2510 Combined with Chemotherapy for First-Line NSCLC Treatment Completes Enrollment of First Patient in Phase Ib/II Clinical Trial-宜明昂科英文

Company News

Home Company News News detail

ImmuneOnco IMM2510 Combined with Chemotherapy for First-Line NSCLC Treatment Completes Enrollment of First Patient in Phase Ib/II Clinical Trial

2025-01-13

578

Previous article：Approval by the NMPA for Clinical Trial of IMM01 (timdarpacept) Combined with IMM2510 (palverafusp α) and with or without Chemotherapy for Advanced Malignant Tumors

Next article：The Phase II clinical trial of IMM27M for estrogen receptor positive (ER+) advanced breast cancer that failed after endocrine therapy or recurred and has enrolled the first patient

Hot recommendation

ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025

The National Medical Products Administration (NMPA) Approved ImmuneOnco’s Clinical Trial Application for Tazlestobart (IMM27M) Combined with Osimertinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Squamous Non-Sma

Further Payment Received Under the License and Collaboration Agreement with Axion Bio for IMM2510 (Palverafusp α) and IMM27M (Tazlestobart)

For more information

Please follow the official wechat public account